MX371279B - Agente profiláctico y/o terapéutico para síntomas conductuales y psicológicos asociados con la enfermedad neurodegenerativa o síntomas impulsivos asociados con enfermedad mental que contiene brexpiprazol o sales del mismo. - Google Patents

Agente profiláctico y/o terapéutico para síntomas conductuales y psicológicos asociados con la enfermedad neurodegenerativa o síntomas impulsivos asociados con enfermedad mental que contiene brexpiprazol o sales del mismo.

Info

Publication number
MX371279B
MX371279B MX2015005174A MX2015005174A MX371279B MX 371279 B MX371279 B MX 371279B MX 2015005174 A MX2015005174 A MX 2015005174A MX 2015005174 A MX2015005174 A MX 2015005174A MX 371279 B MX371279 B MX 371279B
Authority
MX
Mexico
Prior art keywords
symptoms associated
behavioral
prophylactic
salt
therapeutic agent
Prior art date
Application number
MX2015005174A
Other languages
English (en)
Other versions
MX2015005174A (es
Inventor
Maeda Kenji
Nakamura Mai
Sato Shinji
Ishikawa Dai
Original Assignee
Otsuka Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Otsuka Pharma Co Ltd filed Critical Otsuka Pharma Co Ltd
Publication of MX2015005174A publication Critical patent/MX2015005174A/es
Publication of MX371279B publication Critical patent/MX371279B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Dermatology (AREA)

Abstract

La presente invención se refiere a un agente profiláctico y/o terapéutico para los síntomas conductuales y psicológicos asociados con enfermedad neurodegenerativa o síntomas impulsivos asociados con enfermedad mental, que contiene 7-[4-(4--benzo[b]tiofen-4-il-piperazin-1-il)butoxi]-1H-quinolin-2 -ona o una de sus sales como un ingrediente activo.
MX2015005174A 2012-10-25 2013-10-24 Agente profiláctico y/o terapéutico para síntomas conductuales y psicológicos asociados con la enfermedad neurodegenerativa o síntomas impulsivos asociados con enfermedad mental que contiene brexpiprazol o sales del mismo. MX371279B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261718305P 2012-10-25 2012-10-25
US201361782467P 2013-03-14 2013-03-14
PCT/JP2013/079480 WO2014065437A1 (en) 2012-10-25 2013-10-24 Prophylactic and/or therapeutic agent for behavioral and psychological symptoms associated with neurodegenerative disease or impulsive symptoms associated with mental disease containing brexpiprazole or salt thereof

Publications (2)

Publication Number Publication Date
MX2015005174A MX2015005174A (es) 2015-09-04
MX371279B true MX371279B (es) 2020-01-24

Family

ID=49585556

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015005174A MX371279B (es) 2012-10-25 2013-10-24 Agente profiláctico y/o terapéutico para síntomas conductuales y psicológicos asociados con la enfermedad neurodegenerativa o síntomas impulsivos asociados con enfermedad mental que contiene brexpiprazol o sales del mismo.

Country Status (22)

Country Link
US (5) US20150272946A1 (es)
EP (3) EP3848033A1 (es)
JP (6) JP6329140B2 (es)
KR (1) KR102245016B1 (es)
CN (4) CN112402421A (es)
AR (1) AR093247A1 (es)
AU (1) AU2013335613B2 (es)
BR (1) BR112015008759A2 (es)
CA (1) CA2889196C (es)
EA (1) EA201590808A1 (es)
HK (1) HK1212609A1 (es)
IL (1) IL238402B (es)
JO (2) JOP20130313B1 (es)
MX (1) MX371279B (es)
MY (1) MY180185A (es)
NZ (1) NZ708321A (es)
PH (1) PH12015500925B1 (es)
SG (2) SG10201702828TA (es)
TW (1) TWI643620B (es)
UA (1) UA116549C2 (es)
WO (1) WO2014065437A1 (es)
ZA (1) ZA201503640B (es)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8754238B2 (en) 2003-07-22 2014-06-17 Arena Pharmaceuticals, Inc. Diaryl and arylheteroaryl urea derivatives as modulators of the 5-HT2A serotonin receptor useful for the prophylaxis and treatment of disorders related thereto
TWI415845B (zh) 2006-10-03 2013-11-21 Arena Pharm Inc 用於治療與５-ｈｔ2ａ血清素受體相關聯病症之作為５-ｈｔ2ａ血清素受體之調節劑的吡唑衍生物
JP5393677B2 (ja) 2007-08-15 2014-01-22 アリーナ ファーマシューティカルズ， インコーポレイテッド ５−ＨＴ２Ａセロトニン受容体に関連した障害の治療のための５−ＨＴ２Ａセロトニン受容体のモジュレーターとしてのイミダゾ［１，２−ａ］ピリジン誘導体
US20110021538A1 (en) 2008-04-02 2011-01-27 Arena Pharmaceuticals, Inc. Processes for the preparation of pyrazole derivatives useful as modulators of the 5-ht2a serotonin receptor
HRP20180589T1 (hr) 2008-10-28 2018-05-18 Arena Pharmaceuticals, Inc. Pripravci modulatora serotoninskog receptora 5-ht2a koji su korisni za liječenje s njim povezanih poremećaja
WO2010062321A1 (en) 2008-10-28 2010-06-03 Arena Pharmaceuticals, Inc. Processes useful for the preparation of 1-[3-(4-bromo-2-methyl-2h-pyrazol-3-yl)-4-methoxy-phenyl]-3-(2,4-difluoro-phenyl)-urea and crystalline forms related thereto
AU2015250611A1 (en) * 2014-04-22 2016-11-24 H. Lundbeck A/S Combination of brexpiprazole and nalmefene and use thereof for treating substance-related disorders
WO2016115144A1 (en) * 2015-01-12 2016-07-21 Reviva Pharmaceuticals Inc. Methods for treating alzheimer's disease
HK1244449A1 (zh) * 2015-01-12 2018-08-10 雷维瓦药品公司 用於治疗与帕金森病相关联的精神病的方法
RU2017145976A (ru) 2015-06-12 2019-07-15 Аксовант Сайенсиз Гмбх Производные диарил- и арилгетероарилмочевины, применимые для профилактики и лечения нарушения поведения во время REM-фазы сна
TW201720439A (zh) 2015-07-15 2017-06-16 Axovant Sciences Gmbh 用於預防及治療與神經退化性疾病相關的幻覺之作為５－ｈｔ２ａ血清素受體的二芳基及芳基雜芳基脲衍生物
CN105175401A (zh) * 2015-10-16 2015-12-23 北京康立生医药技术开发有限公司 一种依匹哌唑的制备方法
GB201620095D0 (en) * 2016-11-28 2017-01-11 Terali Innov Sas And Univ De Strasbourg And Inserm (Inst Nat De La Sante Et De La Rech Medicale) And Novel use
CN105541819B (zh) * 2016-02-04 2018-09-14 浙江永宁药业股份有限公司 一种依匹唑派的制备方法及其中间体和中间体的制备方法
RU2762896C2 (ru) 2016-12-20 2021-12-23 Лтс Ломанн Терапи-Систем Аг Трансдермальная терапевтическая система, содержащая азенапин
CA3047354A1 (en) 2016-12-20 2018-06-28 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic system containing asenapine and polysiloxane or polyisobutylene
EP3644973B1 (en) 2017-06-26 2021-03-24 LTS LOHMANN Therapie-Systeme AG Transdermal therapeutic system containing asenapine and silicone acrylic hybrid polymer
US10369134B2 (en) 2017-12-05 2019-08-06 Sunovion Pharmaceuticals Inc. Nonracemic mixtures and uses thereof
MX2020005517A (es) 2017-12-05 2020-11-09 Sunovion Pharmaceuticals Inc Formas cristalinas y metodos de produccion de las mismas.
EP3501506B1 (en) 2017-12-19 2019-10-09 Alfred E. Tiefenbacher (GmbH & Co. KG) Pharmaceutical tablet composition comprising brexpiprazole
CN112533593A (zh) 2018-06-20 2021-03-19 罗曼治疗系统股份公司 含有阿塞那平的透皮治疗系统
CN110958876B (zh) 2018-06-20 2020-12-18 罗曼治疗系统股份公司 含有阿塞那平的透皮治疗系统
WO2020247627A1 (en) 2019-06-04 2020-12-10 Sunovion Pharmaceuticals Inc. Modified release formulations and uses thereof
JPWO2021029020A1 (es) * 2019-08-13 2021-02-18
JP7796412B2 (ja) * 2020-06-24 2026-01-09 国立大学法人北海道大学 血液脳脊髄関門保護剤
CN112137994B (zh) * 2020-09-15 2022-10-14 中山大学 小分子化合物在制备抗丝状病毒药物中的应用
US11229644B1 (en) * 2020-12-31 2022-01-25 Lake O'hara Llc Methods of treating psychiatric disorders in obese patients with brexpiprazole
CN115429753B (zh) * 2021-06-02 2024-08-06 山东百诺医药股份有限公司 布瑞哌唑口服混悬液
US12310974B1 (en) 2023-12-19 2025-05-27 Samuel Aballea Method of treating post-traumatic stress disorder with carpipramine
CN118078788A (zh) * 2024-04-03 2024-05-28 中国科学院昆明动物研究所 米托蒽醌甲磺酸盐在制备治疗单胺缺乏导致的疾病产品中的应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI320783B (en) * 2005-04-14 2010-02-21 Otsuka Pharma Co Ltd Heterocyclic compound
JP4315393B2 (ja) 2005-04-14 2009-08-19 大塚製薬株式会社 複素環化合物
JP4540700B2 (ja) * 2006-10-13 2010-09-08 大塚製薬株式会社 医薬
JP2011136906A (ja) * 2008-04-18 2011-07-14 Otsuka Pharmaceut Co Ltd 複素環化合物
AR085840A1 (es) * 2011-04-05 2013-10-30 Otsuka Pharma Co Ltd Medicamento que contiene un compuesto que es 7-[4-(4-benzo[b]tiofen-4-il-piperazin-1-il)butoxi]-1h-quinolin-2-ona
AR090775A1 (es) * 2012-04-23 2014-12-03 Otsuka Pharma Co Ltd Preparado inyectable
TWI562991B (en) * 2012-04-23 2016-12-21 Otsuka Pharma Co Ltd Dihydrate of benzothiophene compound or of a salt thereof, and process for producing the same
EP2822136B1 (en) * 2013-07-03 2018-08-29 Siemens Aktiengesellschaft Method and arrangement for transferring electrical power for subsea applications

Also Published As

Publication number Publication date
US20220370442A1 (en) 2022-11-24
UA116549C2 (uk) 2018-04-10
JP6329140B2 (ja) 2018-05-23
JP2018138555A (ja) 2018-09-06
US20150272946A1 (en) 2015-10-01
US20250099459A1 (en) 2025-03-27
JP2020045345A (ja) 2020-03-26
US20190314367A1 (en) 2019-10-17
EP2911670A1 (en) 2015-09-02
JOP20210047A1 (ar) 2021-03-11
SG10201702828TA (en) 2017-05-30
IL238402B (en) 2018-11-29
SG11201503152TA (en) 2015-05-28
KR102245016B1 (ko) 2021-04-26
US20170258787A1 (en) 2017-09-14
KR20150074156A (ko) 2015-07-01
AU2013335613A1 (en) 2015-06-04
EP3848033A1 (en) 2021-07-14
JP2021181448A (ja) 2021-11-25
BR112015008759A2 (pt) 2017-07-04
AR093247A1 (es) 2015-05-27
TWI643620B (zh) 2018-12-11
NZ708321A (en) 2019-03-29
CN104755082A (zh) 2015-07-01
EA201590808A1 (ru) 2015-08-31
PH12015500925B1 (en) 2021-09-08
CA2889196C (en) 2021-02-16
CN112402421A (zh) 2021-02-26
JP2023123441A (ja) 2023-09-05
EP4674482A2 (en) 2026-01-07
TW201427665A (zh) 2014-07-16
ZA201503640B (en) 2016-08-31
JP2015535211A (ja) 2015-12-10
IL238402A0 (en) 2015-06-30
EP4674482A3 (en) 2026-01-21
PH12015500925A1 (en) 2015-06-29
CN108578408A (zh) 2018-09-28
MX2015005174A (es) 2015-09-04
CA2889196A1 (en) 2014-05-01
CN114712360A (zh) 2022-07-08
WO2014065437A1 (en) 2014-05-01
MY180185A (en) 2020-11-24
AU2013335613B2 (en) 2018-07-12
JP2025093929A (ja) 2025-06-24
HK1212609A1 (zh) 2016-06-17
JOP20130313B1 (ar) 2021-08-17

Similar Documents

Publication Publication Date Title
JOP20210047A1 (ar) عامل وقائي و/أو علاجي للأعراض السلوكية والنفسية المصحوبة بمرض تنكسي عصبي أو الأعراض الإندفاعية المصحوبة بمرض ذهني، يحتوي على بريكسبيرازول أو ملحه
GEP20166554B (en) Nitrogenated heterocyclic compound
TN2015000278A1 (en) Autotaxin inhibitors
MX2014012527A (es) Dihidrato de un compuesto de benzotiofeno o de una sal del mismo y proceso para producir el mismo.
MY173843A (en) Amidine substituted ?-lactam compounds, their preparation and use as antibacterial agents
TN2014000319A1 (en) Imidazopyrrolidinone compounds
PH12014501967A1 (en) Benzodioxanes in combination with other actives for inhibiting leukotriene production
MA35816B1 (fr) Dérivés d'aniline, leur préparation et leur application thérapeutique
UA110213C2 (en) Use of sigma-ligand induced opioid hyperalgesia
MX344846B (es) Combinacion de granulos cargados activos con activos adicionales.
TN2012000488A1 (en) Pharmaceutical compositions comprising hydromorphone and naloxone
PH12013501481A1 (en) Disialyllacto-n-tetraose (dslnt) or variants, isomers, analogs and derivatives thereof to prevent or inhibit bowel disease
AR093527A1 (es) 6-((S)-1-1-[5-(2-HIDROXI-ETOXI)-PIRIDIN-2-IL]1H-PIRAZOL-3-IL-ETIL)-3H-1,3-BENZOTIAZOL-2-ONA COMO UN ANTAGONISTA DEL RECEPTOR AMPA DEPENDIENTE DE TARP-g 8
UA112488C2 (uk) Три(гетеро)арилпіразоли і їх застосування
WO2014056779A8 (de) Arzneimittel zur prophylaxe und behandlung einer neurodegenerativen erkrankung
WO2012169785A3 (en) Symmetrically structured quinazoline derivatives
IT1403778B1 (it) Veicolo trainato, particolarmente atto all'impiego agricolo o forestale
GB201206984D0 (en) New therapeutic use
WO2014147578A3 (en) Antibacterial compounds against drug resistant bacteria
MD4291B1 (ro) Preparat medicamentos pentru tratamentul otitelor
IN2014KN02584A (es)
EA202193278A1 (ru) Средство для профилактики и/или лечения поведенческих и психотических симптомов, связанных с нейродегенеративным заболеванием, или симптомов импульсивности, связанных с психическим заболеванием, содержащее брекспипразол или его соль
IN2014DE00700A (es)
GEP201606554B (en) Nitrogenated heterocyclic compound
UA105703C2 (uk) 7-бром-5-феніл-3-ариламіно-1,2-дигідро-3н-1,4-бенздіазепін-2-они як анальгетичні агенти

Legal Events

Date Code Title Description
FG Grant or registration